-
Mashup Score: 15At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens - 14 hour(s) ago
Background: Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial management a challenging phase. Methods: This difficulty in our center led to the establishment of an At-Home (AH) program for ramp-up and follow-up patients during the VenAza combination induction phase focused on therapy administration, patient and caregiver education, and management of adverse events (AEs). A total of 70 patients with newly diagnosed acute myeloid leukemia (ND-AML) or relapsed/refractory AML (R/R AML) were treated with VenAza from March 2019 to May 2022. We compared outcomes between patients managed with a hospital-based (inpatient) approach and those managed through the AH program. Results: Despite most patients experiencing grade 3–4 cytopenias (96.9%), the incidence of serious infections and other AEs was comparable between both groups, with
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Sumando fuerzas contra los devastadores efectos de la DANA - 2 month(s) ago
Las fuertes lluvias que han azotado la Comunidad Valenciana, Castilla La-Mancha y Andalucía han causado estragos. Cruz Roja se moviliza y hace un llamamiento a la población para combatir las consecuencias de la DANA. Las fuertes lluvias que han azotado la Comunidad Valenciana, Castilla La-Mancha y Andalucía han causado estragos. Cruz Roja se moviliza y hace un llamamiento a la población para combatir las…
Source: www2.cruzroja.esCategories: General Medicine News, Hem/OncsTweet-
Donaciones a la Cruz Roja para los afectados por la #dana en Valencia. Sumando fuerzas contra los devastadores efectos de la DANA https://t.co/BSpoS1B75N
-
-
Mashup Score: 6Registro en la Sede Virtual del GETH - 1 year(s) ago
GETH Sede Virtual Registro en la Sede Virtual del GETH Solicitud de Inscripción al webinar: PRESENTACION DE LA GUIA DE MANEJO AMBULATORIO DE PACIENTES RECEPTORES DE TERAPIA CART – 10 ENERO 2024, 16:00 hLa inscripción es GRATUITA y quedará formalizada una…
Source: sedevirtual.geth.esCategories: General Medicine News, Hem/OncsTweet-
Link para la inscripción: https://t.co/osmor3FmyF
-
-
Mashup Score: 0Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia - 2 year(s) ago
Key Points. HLA-haploidentical BMT with PTCy as upfront therapy in patients with SAA results in survival >90% and low morbidity/mortality.More than 35% of pa
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia https://t.co/fnwmppPFUy
-
-
Mashup Score: 0When Dying Patients Want Unproven Drugs - 2 year(s) ago
Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.
Source: The New YorkerCategories: Hem/Oncs, Latest HeadlinesTweet-
When Dying Patients Want Unproven Drug. @the_newyorker https://t.co/rdqnpK3hID
-
-
Mashup Score: 0
Introduction: The SARS-CoV-2 pandemic generated the need to keep immunosuppressed patients away from hospital institutions for as long as possible. This in turn stimulated the implementation of a home hospitalization model for autologous hematopoietic stem-cell transplantation (HSCT). Purpose: To analyze whether there are significant differences in post-transplantation complications related to…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Complications Associated with Peripherally Inserted Central Catheters (PICC) in Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Home Hospitalization https://t.co/UdqlJraIR2 #mdpiijerph a través de @IJERPH_MDPI @WHAH_cong @Sociedad_SEHAD
-
-
Mashup Score: 4Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes - 2 year(s) ago
Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid leukemia (AML). In a single-center cohort of 219 CMML patients, we explored the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and clonal evolution…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Amazing work by Dr. Castaño-Diez et al, on real-world data in 219 #CMML patients! #OpenAccess Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes https://t.co/QpCCKRmXZx vía @Cancers_MDPI
-
-
Mashup Score: 5Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia - 3 year(s) ago
Key Points. A subset of patients receiving ≥12 months of VEN-based therapy can experience durable treatment-free remission (TFR) after ceasing therapyThe risk o
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet-
Mesmerized by this graph, were patients stop Ven/HMA treatment and continue in remission at 72m, predominately NPM1 mutated AML 😮 #AML #OncoAlert Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia https://t.co/5Xag1FPw5T https://t.co/MfeeW9upId
-
-
Mashup Score: 27th International Transplant Course - 3 year(s) ago
Dear Colleagues, It is our great pleasure to welcome you on behalf of our society to the 7th International Transplant Course 2-4 September 2022. I am so excited and relieved to announce to you that this year we are back to ‘normal’ with a regular face-to-face meeting in the heart of Barcelona! We have worked hard to provide a broad, up-to-date and concise overview of all relevant topics in…
Source: EBMTCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TheEBMT_Trainee: Happy to announce the 7th @TheEBMT International Transplant Course 2-4 Sep in Barcelona https://t.co/L3JPxqJrrN NEW:…
-
-
Mashup Score: 2How I treat acute myeloid leukemia in the era of new drugs - 3 year(s) ago
The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to ta…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Definitely, @BloodJournal How I treat are my favorites... #leusm How I treat acute myeloid leukemia in the era of new drugs https://t.co/CStvkBo5uL https://t.co/BQMFxRakQ8
-
Thrilled to share our latest study: “At-Home (AH) care program for Acute Myeloid Leukemia (AML) patients undergoing induction therapy with Venetoclax + Azacitidine (VenAza) 🧵 https://t.co/JlZXc3XYUf #mdpicancers via @Cancers_MDPI